Central Serous Chorioretinopathy
1
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Nova Eye MedicalAustralia - Kent Town
1 program2RT subthreshold nanosecond laser - activeN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Alconantioxidants tablets
GenentechrhuFab V2 [ranibizumab]
Nova Eye Medical2RT subthreshold nanosecond laser - active
Clinical Trials (3)
Total enrollment: 129 patients across 3 trials
High-dose Antioxidants for Central Serous Chorioretinopathy
Start: Dec 2004Est. completion: Jun 200960 patients
Phase 2Completed
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
Start: Aug 20069 patients
Phase 1Completed
Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy
Start: Oct 2022Est. completion: Dec 202460 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 129 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.